Sign in

SINT on Nasdaq

Sintx Technologies, Inc.

Sintx Technologies, Inc. is an American surgical and medical instruments and apparatus company.1 It is headquartered in Salt Lake City, Utah.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with RenovoRx, Inc., PetVivo Holdings, Inc. or SeaStar Medical Holding Corp, or pick any stock.

  • TickerSINT on Nasdaq1
  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersSalt Lake City, Utah1
  • Incorporated inDE2
  • Business address1885 West 2100 Street, Salt Lake City, Ut 841192
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Patent No. 11,591,217, creates a family of patents focused on addressing the antimicrobial agribiotech market.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

45.3%Gross margin4
-1053.1%Operating margin4
-1018.1%Net margin4
-64.7%Revenue growth, 20254
-353.8%Return on equity4
-$8.8MFree cash flow4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Product brought in 72% of the revenue Sintx Technologies, Inc. broke down this way in fiscal 2025.

  1. Product$729.0K472%down 41% from 2024
  2. Grant and Contract$289.0K428%down 82% from 2024
Products and services by year
Products and services20242025
Product$1.2M$729.0K
Grant and Contract$1.6M$289.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue11¢$557.0K
  • Research and development89¢$4.6M

Out of $1.0M in revenue.4 The company lost money this year.

Financial statements

Revenue567894$1.0M in 2025+48% since 2019
0$1.0M$2.0M$3.0M2019: $689.0K$689.0K20192020: $594.0K$594.0K2020−14%2021: $606.0K$606.0K2021+2%2022: $1.6M$1.6M2022+158%2023: $2.6M$2.6M2023+68%2024: $2.9M$2.9M2024+10%2025: $1.0M$1.0M2025−65%
Gross profit567894$461.0K in 2025+234% since 2019
0$1.0M$2.0M$3.0M2019: $138.0K$138.0K20192020: $119.0K$119.0K2020−14%2021: $157.0K$157.0K2021+32%2022: $1.3M$1.3M2022+725%2023: $1.8M$1.8M2023+42%2024: $2.1M$2.1M2024+13%2025: $461.0K$461.0K2025−78%
Operating income567894-$10.7M in 2025+63% since 2019
-$15.0M-$10.0M-$5.0M02019: -$6.6M-$6.6M20192020: -$8.5M-$8.5M2020+29%2021: -$10.6M-$10.6M2021+25%2022: -$11.3M-$11.3M2022+7%2023: -$13.4M-$13.4M2023+18%2024: -$14.0M-$14.0M2024+5%2025: -$10.7M-$10.7M2025−24%
Net income567894-$10.4M in 2025+116% since 2019
-$15.0M-$10.0M-$5.0M02019: -$4.8M-$4.8M20192020: -$7.0M-$7.0M2020+47%2021: -$9.3M-$9.3M2021+32%2022: -$12.0M-$12.0M2022+29%2023: -$8.3M-$8.3M2023−31%2024: -$11.0M-$11.0M2024+33%2025: -$10.4M-$10.4M2025−6%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Total revenue$1.0M$2.9M
Cost of revenue$557.0K$811.0K
Gross profit$461.0K$2.1M
Research and development$4.6M$5.2M
General and administrative$6.2M$4.0M
Sales and marketing$242.0K$614.0K
Armor exit costs$4.6M
Reduction in force$407.0K
Grant and contract expenses$156.0K$1.3M
Total operating expenses$11.2M$16.1M
Loss from operations-$10.7M-$14.0M
Interest expense-$52.0K-$29.0K
Interest income$175.0K$107.0K
Gain (loss) on the disposal of assets$327.0K-$19.0K
Change in fair value of derivative liabilities-$124.0K$3.5M
Offering costs of derivative liabilities-$550.0K
Other income (expense)$31.0K$39.0K
Total other income (expense), net$357.0K$3.0M
Net loss before income taxes-$10.4M-$11.0M
Net loss-$10.4M-$11.0M
Deemed dividend related to warrant inducement-$6.7M
Net loss attributable to common stockholders-$17.1M-$11.0M
Basic net loss-$4-$15
Basic deemed dividend related to warrant inducement-$2
Basic attributable to common stockholders-$6.16-$14.87
Diluted net loss-$4-$15
Diluted - deemed dividend related to warrant inducement-$2
Diluted attributable to common stockholders-$6.16-$15.19
Basic2.8M shares741.2K shares
Diluted2.8M shares744.8K shares

Compare Sintx Technologies, Inc. with another company

Corporate structure

Sintx Technologies, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Sintx Technologies, Inc.

  • Sintx Technologies, Inc. Salt Lake City, Utah

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Sintx Technologies, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$3.5M4 Dec 31, 2025$4.0M4 Dec 31, 2024−11.1%
Accumulated depreciation$3.1M4 Dec 31, 2025$3.0M4 Dec 31, 2024+0.1%
Property and equipment, net$476.0K4 Dec 31, 2025$922.0K4 Dec 31, 2024−48.4%
Operating-lease assets (leased space)$2.5M4 Dec 31, 2025$3.2M4 Dec 31, 2024−22.2%

Real estate and locations

ItemLatestA year beforeChange
Area of land30,764 sq ft4 Dec 31, 202530,764 sq ft9 Dec 31, 20240%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$4.1M4 Dec 31, 2025$3.6M4 Dec 31, 2024+15.1%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$302.0K4 Dec 31, 2025$6.2M12 Dec 31, 2017−95.1%
Intangible assets, net (excluding goodwill)$142.0K4 Dec 31, 2025$16.0K4 Dec 31, 2024+787.5%
Finite-lived intangibles, gross$195.0K4 Dec 31, 2025$50.0K4 Dec 31, 2024+290.0%
Accumulated amortization$53.0K4 Dec 31, 2025$34.0K4 Dec 31, 2024+55.9%
Finite-lived intangibles, net$142.0K4 Dec 31, 2025$16.0K4 Dec 31, 2024+787.5%

Inventory

ItemLatestA year beforeChange
Inventory, total$825.0K4 Dec 31, 2025$502.0K4 Dec 31, 2024+64.3%
Work in process$296.0K4 Dec 31, 2025$182.0K4 Dec 31, 2024+62.6%
Finished goods$346.0K4 Dec 31, 2025$156.0K4 Dec 31, 2024+121.8%

Properties, in its own words

Our 30,764 square foot corporate office and manufacturing facilities are located in Salt Lake City, Utah. We occupy these facilities pursuant to a lease that expires in October 2031. Pursuant to the terms of the lease agreement, we may extend the lease for one additional period of five years.

We also lease a 10,936 square foot facility located in Salt Lake City, Utah. This facility is pursuant to a lease that expires in October 2031. As of November 2025, this facility is subleased through October 2031.

The rest of Item 2

We believe that our existing facilities are adequate for our current and projected needs for the foreseeable future.

Item 2 of the 10-K filed Mar 20, 2026.3

Leadership

Who has led Sintx Technologies, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Bhajanjit Bal2015–2017

President

  1. Bhajanjit Bal2015–2016
  2. Robert Ryan Elmore2026–now

Chief financial officer

  1. Jay M. Moyes2014
  2. Ty Lombardi2016
  3. Kevin Trask2025–now

Chief operating officer

  1. Kevin Davis2014
  2. David Francis O'Brien2020
201520202025
Board members and other officers (16)

Former names

  • AMEDICA CORPDec 31, 2012 to Oct 5, 20182

Timeline

  1. Oct 9, 20268-K Other events34
  2. Oct 1, 20268-K Results of operations; Regulation FD disclosure35
  3. Aug 13, 20268-K Regulation FD disclosure; Other events36
  4. Aug 11, 20268-K Results of operations; Regulation FD disclosure37
  5. Jul 23, 20268-K Regulation FD disclosure38
  6. Jul 2, 20268-K Entered a material agreement; Unregistered sale of shares39
  7. Jun 3, 20268-K Entered a material agreement; Unregistered sale of shares; Other events40
  8. May 27, 20268-K Listing notice or transfer41
  9. Feb 18, 20268-K Executive or director change42
  10. Dec 1, 20258-K Regulation FD disclosure43
  11. Nov 13, 20258-K Results of operations; Regulation FD disclosure44
  12. Oct 3, 20258-K Entered a material agreement45
  13. Jan 9, 2015New chief executive Bhajanjit Bal becomes CEO13

Calendar

Coming up

  1. Nov 11, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($3.46) a share, on Nov 12, 2025.46

When it reported results

  1. Oct 1, 2026Reported quarterly or annual results35
  2. Aug 11, 2026Reported quarterly or annual results37
  3. Nov 13, 2025Reported quarterly or annual results44
  4. May 15, 2025Reported quarterly or annual results47
  5. Jan 23, 2024Reported quarterly or annual results48
  6. Jan 25, 2023Reported quarterly or annual results49

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

195 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 64 major events, 25 insider forms, 18 large holders, 68 other. The latest 20:

  1. Oct 9, 20268-K EDGAR
  2. Oct 1, 20268-K EDGAR
  3. Aug 18, 2026EFFECT EDGAR
  4. Aug 13, 20268-K EDGAR
  5. Aug 13, 2026S-3 EDGAR
  6. Aug 13, 2026SCHEDULE 13G EDGAR
  7. Aug 11, 20268-K EDGAR
  8. Aug 11, 202610-Q EDGAR
  9. Jul 23, 20268-K EDGAR
  10. Jul 2, 20268-K EDGAR
  11. Jun 30, 2026EFFECT EDGAR
  12. Jun 25, 2026S-3 EDGAR
  13. Jun 9, 2026SCHEDULE 13G EDGAR
  14. Jun 9, 2026SCHEDULE 13G EDGAR
  15. Jun 3, 20268-K EDGAR
  16. May 27, 20268-K EDGAR
  17. May 15, 202610-Q EDGAR
  18. Apr 14, 20264 EDGAR
  19. Mar 20, 202610-K EDGAR
  20. Mar 18, 20264 EDGAR

The 195 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

18 open-market trades by officers, directors and large owners since October 2021: 17 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 2, 2026Lyons Christopher MichaelDirectorBuy7,534$2.90$21.8KForm 4
Feb 25, 2026Lyons Christopher MichaelDirectorBuy758$2.96$2.2KForm 4
Feb 23, 2026MOYES JAY MDirectorBuy1,000$2.91$2.9KForm 4
Feb 18, 2026Anderson Mark LewisDirectorBuy3,000$3.02$9.1KForm 4
Dec 8, 2025Honigblum Gregg R.Chief Investment OfficerBuy8,200$4.26$34.9KForm 4
Dec 5, 2025Honigblum Gregg R.Chief Investment OfficerBuy65,000$3.93$255.3KForm 4
Nov 7, 2025Honigblum Gregg R.Chief Investment OfficerBuy10,000$3.19$31.9KForm 4
Oct 20, 2025Olson Eric K.Chairman, President and CEOBuy5,800$3.40$19.7KForm 4
Aug 26, 2025MOYES JAY MDirectorBuy3,000$3.59$10.8KForm 4
Aug 26, 2025Honigblum Gregg R.Chief Investment OfficerBuy50,000$3.70$185.0KForm 4
Aug 22, 2025Olson Eric K.Chairman, President and CEOBuy10,475$3.58$37.5KForm 4
Jun 18, 2025Anderson Mark LewisDirectorBuy10,000$3.30$33.0KForm 4
Apr 24, 2025Anderson Mark LewisDirectorBuy5,000$2.36$11.8KForm 4
Apr 23, 2025Olson Eric K.Chairman, President and CEOBuy14,264$1.94$27.7KForm 4
Apr 22, 2025Honigblum Gregg R.Chief Investment OfficerBuy4,000$1.79$7.2KForm 4
Apr 22, 2025Olson Eric K.Chairman, President and CEOBuy236$1.73$408Form 4
Apr 22, 2025Honigblum Gregg R.Chief Investment OfficerBuy10,000$1.77$17.7KForm 4
Nov 29, 2022Truetzel David W.DirectorSale67$0.12$8Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2024B. Sonny Bal$253.8K$440.7K61
2024David O’Brien$220.8K$369.8K61
2024Eric Olson62$136.0K$194.6K61
2023Chief Executive Officer$412.7K$537.3K61
2023Chief Operating Officer$367.3K$453.6K61

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Bleichroeder LP523,013$978.0K0.2%New
Stonepine Capital Management, LLC209,205$332.5K0.3%New
Veracity Capital LLC76,674$143.4K0.0%No change
Citadel Advisors LLC31,930$59.7K0.0%New
Geode Capital Management, LLC30,101$56.3K0.0%−2,043
Vanguard Fiduciary Trust Co23,531$44.0K0.0%No change
Vanguard Capital Management LLC20,905$39.1K0.0%No change
State Street Corp13,302$24.9K0.0%No change
UBS Group AG11,921$22.3K0.0%+6,968
Virtus Wealth Solutions LLC10,000$18.7K0.0%No change
Tower Research Capital LLC (TRC)2,850$5.3K0.0%+1,683
Signaturefd, LLC1,717$3.2K0.0%+572
SBI Securities Co., Ltd.14$260.0%No change
Hrt Financial LP12,831$230.0%New
Morgan Stanley1$20.0%−17
National Bank Of Canada /fi/1$20.0%No change
Allworth Financial LP1$20.0%No change
Osaic Holdings, Inc.1$20.0%−1
Cornerstone Planning Group LLC1$20.0%No change
Royal Bank Of Canada39$00.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Sintx Technologies, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSintx Technologies, Inc.1
  • CIK0001269026
  • Employer ID (EIN)84-13752993
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address1885 West 2100 Street, Salt Lake City, UT 841191
  • Phone801-839-35161
  • Shares outstanding6,664,534 as of Aug 5, 202611
  • Public float$7.7M as of Jun 30, 20253
  • AuditorTANNER LLP, Lehi, Utah PCAOB ID 270; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceNov 3, 20031
  • Filings657 in all: 8-K (203), 4 (77), 10-Q (38), 424B3 (34), S-1/A (34), CORRESP (29), 3 (20), EFFECT (20)1
    All 47 form types

    424B5 (18), UPLOAD (16), 10-K (13), DEF 14A (12), SC 13G/A (12), S-3 (11), SC 13G (11), S-1 (10), 10-Q/A (9), SCHEDULE 13G (8), 424B4 (7), D (7), DEFA14A (7), PRE 14A (7), FWP (4), REGDEX/A (4), SCHEDULE 13G/A (4), 10-K/A (3), 8-K/A (3), CERTNAS (3), D/A (3), NT 10-Q (3), REGDEX (3), S-1MEF (3), S-3/A (3), S-8 (3), 8-A12B (2), POS AM (2), 144 (1), CT ORDER (1), DEFN14A (1), DEFR14A (1), DRS (1), NT 10-K (1), POS EX (1), PREC14A (1), RW (1), SC 13D (1), SC 13D/A (1)

  • Latest filingsAnnual report (10-K) Mar 20, 2026
    Quarterly report (10-Q) Aug 11, 2026
    Proxy statement (DEF 14A) Jul 31, 2025
    Latest 8-K (8-K) Oct 9, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.01 par valueSINTNasdaq

From the cover page of the 10-K filed Mar 20, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks Sintx Technologies, Inc. names in Item 1A of its 10-K filed Mar 20, 2026: 39 risks under these headings, as written.3

  • In addition to the other information contained in this Annual Report, the following risk factors should be considered carefully in evaluating our company. Our business, financial condition, liquidity or results of operations could be materially adversely affected by any of these risks.
  • Risks Related to Our Capital Resources and Impairments
  • We will require additional financing and our failure to obtain additional funding would force us to delay, reduce or eliminate our product development programs or commercialization efforts.
  • Raising additional capital by issuing securities or through debt financings or licensing arrangements will likely cause dilution to existing stockholders, restrict our operations or require us to relinquish proprietary rights.
  • Risks Related to Our Business and Strategy
  • We have incurred net losses since our inception and anticipate that we will continue to incur net losses for the foreseeable future. We may never achieve or sustain profitability.
  • Our success depends on our ability to successfully commercialize advanced ceramic products for biomedical, and antipathogenic applications, which to date have experienced only limited market acceptance.
  • Our biomedical products may not achieve market acceptance or commercial success.
  • The orthopedic market is highly competitive, and we may not be able to compete effectively against the larger, well-established companies that dominate this market or emerging and small innovative companies that may seek to obtain or increase their share of the market.
  • The manufacturing process for our silicon nitride products is complex and requires sophisticated state-of-the-art equipment, experienced manufacturing personnel and highly specialized knowledge. If we are unable to manufacture our silicon nitride products on a timely basis consistent with our quality standards, our results of operation will be adversely impacted.
  • We depend on a limited number of third-party suppliers for key raw materials used in the manufacturing of our silicon nitride products, and the loss of these third-party suppliers or their inability to supply us with adequate raw materials could harm our business.
  • In order to be successful, we must expand our available product lines by commercializing new product candidates, but we may not be able to do so in a timely fashion and at expected costs, or at all.
The other 29 risks
  • We rely on both strategic partners and our own commercialization capabilities to develop and market our product candidates, and if these efforts are unsuccessful, we may not achieve profitability.
  • Building and managing an in-house sales and distribution organization subjects us to significant operational, financial, and execution risks.
  • Part of our strategy is to establish and develop OEM partnerships and arrangements, which subjects us to various risks.
  • If hospitals and other healthcare providers are unable to obtain coverage or adequate reimbursement for procedures performed using our medical products, our products may not achieve widespread adoption.
  • A pandemic, epidemic or outbreak of an infectious disease in the United States or elsewhere may adversely affect our business, operations, and financial condition.
  • Prolonged negative economic conditions in domestic and international markets may adversely affect us, our suppliers, partners and consumers, and could harm our financial position.
  • We are dependent on our senior management team, engineering team, and external advisors, and the loss of any of them could harm our business. We may not have sufficient personnel to effectuate our business strategy due to our recent reduction in force.
  • If we experience significant disruptions in our information technology systems, our business, results of operations and financial condition could be adversely affected.
  • Cybersecurity risks and failures of our information technology systems could disrupt our operations, compromise confidential information, and materially adversely affect our business.
  • Risks Related to Regulatory Approval of Our Products and Other Government Regulations
  • Contracting with government entities exposes us to additional risks inherent in the government procurement process.
  • We design, manufacture and service products that incorporate advanced technologies; the introduction of new products and technologies involves risks, and we may not realize the degree or timing of benefits initially anticipated; competition may reduce our revenues and segment share and limit our future opportunities.
  • Exports and imports of certain of our products are subject to various export control, sanctions and import regulations and may require authorization from regulatory agencies of the U.S. or other countries.
  • Our long-term success depends on our ability to obtain and maintain regulatory clearances and approvals for our medical products and product candidates, and we may be unable to do so in a timely manner or at all.
  • The safety and effectiveness of our products are not supported by long-term clinical data, and they may prove to be less safe or effective than our preclinical testing or limited clinical experience indicate.
  • We may be required to generate clinical or additional supporting data for certain product candidates, which could increase costs and delay commercialization.
  • Our relationships with healthcare providers, distributors, and third-party payers are subject to complex healthcare fraud and abuse, transparency, and privacy laws, and noncompliance could result in significant penalties and reputational harm.
  • Changes in effective tax rates or adverse outcomes resulting from examination of our income or other tax returns could adversely affect our results of operations and financial condition.
  • Changes in tax laws or their interpretation could adversely affect our business and the value of our securities.
  • Changes in healthcare laws, regulations, and reimbursement policies may increase our costs, delay regulatory review, and adversely affect pricing and demand for our products.
  • Risks Related to Our Intellectual Property and Litigation
  • If the combination of patents, trade secrets and contractual provisions that we rely on to protect our intellectual property is inadequate, our ability to commercialize our products successfully will be harmed, and we may not be able to operate our business profitably.
  • We have no patent protection covering the composition of matter for our solid silicon nitride or for all of the components of the process we use for manufacturing our silicon nitride, and competitors may create silicon nitride formulations substantially similar to ours.
  • We could become subject to intellectual property litigation that could be costly, result in the diversion of management’s time and efforts, require us to pay damages, prevent us from marketing our commercially available products or product candidates and/or reduce the margins we may realize from our products that we may commercialize.
  • We may be subject to damages resulting from claims that we have wrongfully used or disclosed alleged trade secrets of our competitors or are in breach of non-competition agreements with our competitors or non-solicitation agreements.
  • If our advanced ceramic products or our product candidates conflict with the rights of others, we may not be able to manufacture or market our products or product candidates, which could have a material and adverse effect on us.
  • Risks Related to Potential Litigation from Operating Our Business
  • We may become subject to potential product liability claims, and we may be required to pay damages that exceed our insurance coverage.
  • Any claims relating to our improper handling, storage or disposal of biological or hazardous materials could be time consuming and costly.
  • Risks Related to Public Companies
  • We are a “smaller reporting company” and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.
  • We incur substantial costs as a result of being a public company and our management expects to devote substantial time to public company compliance programs.
  • We may not be able to maintain our listing on the Nasdaq Capital Market, which would adversely affect the price and liquidity of our common stock.

Legal proceedings

We are currently not a party to any material legal proceedings. However, our industry is characterized by frequent claims and litigation, including claims regarding intellectual property and product liability. As a result, we may be subject to various legal proceedings in the future.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
    SEC EDGAROther events
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61